PB1763: A PHASE 1/2 STUDY TO EVALUATE PONATINIB WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RELAPSED/RESISTANT/INTOLERANT PHILADELPHIA CHROMOSOME–POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR WITH T315I MUTATION

• L. Gore,
• M. Loh,
• C.-H. Pui,
• Y. Matloub,
• M. J. Hanley,
• J. Du,
• M. Hennessy,
• M. Granier,
• A. Biondi,
• L. Silverman

Affiliations

L. Gore

1 University of Colorado Cancer Center and Children’s Hospital, Aurora, CO

M. Loh

2 University of Washington, Seattle, WA

C.-H. Pui

3 St. Jude Children’s Research Hospital, Memphis, TN

Y. Matloub

4 Takeda Development Center Americas, Inc., Lexington, MA, United States of America

M. J. Hanley

4 Takeda Development Center Americas, Inc., Lexington, MA, United States of America

J. Du

4 Takeda Development Center Americas, Inc., Lexington, MA, United States of America

M. Hennessy

4 Takeda Development Center Americas, Inc., Lexington, MA, United States of America

M. Granier

5 Incyte Biosciences Intl Sarl, Morges, Switzerland

A. Biondi

6 Clinica Pediatrica Universita Milano-Bicocca, Monza, Italy

L. Silverman

7 Dana Farber/Boston’s Children’s Hospital, Boston, MA, United States of America